Related Experiment Video

Updated: Nov 17, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K

Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection

Pere Pericas1,2, Caterina Mas-Lladó3,4, Maria Francisca Ramis-Barceló3,4

  • 1Cardiology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120, Palma, Balearic Islands, Spain. papericas@hotmail.com.

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
|February 18, 2021
PubMed

Insights

Sacubitril/valsartan (S-V) significantly improved diastolic function in heart failure with reduced ejection fraction (HFrEF) patients. Improvements were most notable in those with initially advanced diastolic dysfunction and better functional class post-treatment.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Echocardiography

Background:

  • Sacubitril/valsartan (S-V) is known to improve clinical outcomes in heart failure with reduced ejection fraction (HFrEF).
  • This benefit is primarily attributed to improvements in systolic function.
  • Diastolic function changes have been less explored.

Purpose of the Study:

  • To evaluate longitudinal changes in echocardiographic diastolic function parameters.
  • To assess the impact of Sacubitril/valsartan (S-V) on diastolic dysfunction (DD) in HFrEF patients.

Main Methods:

  • Prospective collection of echocardiographic parameters (DD grade, E/e' ratio, left atrial strain) and NYHA class.
  • Evaluation of 65 HFrEF patients at baseline and 6-month follow-up.
  • Analysis of changes in systolic and diastolic function parameters.

Main Results:

  • Significant reduction in DD grade (p < 0.001) and E/e' ratio (p = 0.004) after S-V treatment.
  • Marked improvement in DD grade for patients with initial grades 2 and 3.
  • Improvement in left ventricle ejection fraction (p < 0.001) and NYHA class (p = 0.001).

Conclusions:

  • Sacubitril/valsartan (S-V) improves diastolic function in HFrEF patients, beyond systolic improvements.
  • Echocardiographic diastolic improvements correlate with better NYHA functional class.
  • S-V offers a comprehensive benefit for HFrEF patients.
Abstract

Keywords:
Diastolic functionHeart failureSacubitril–valsartanSystolic function

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.7K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

19.7K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
88
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
608
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
210
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
168
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
553